Please login to the form below
IGAS
This page shows the latest IGAS news and features for those working in and with pharma, biotech and healthcare.
Novartis’ iptacopan scores positive results in rare blood disorder PNH
involvement. This includes IgA nephropathy (IgAN), atypical haemolytic uremic syndrome (aHUS), and membranous nephropathy (MN). ... The European Medicines Agency (EMA) has also granted iptacopan a PRIME designation in C3G, as well as an orphan drug
Latest news
-
Novartis receives FDA breakthrough therapy designation for rare disease med
This includes IgA nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and membranous nephropathy (MN). ... The European Medicines Agency (EMA) has also granted iptacopan a PRIME designation in C3G, as well as an orphan drug designation for the
-
Incyte’s JAK inhibitor cream clears second eczema trial
In both trials, significantly more patients treated with ruxolitinib cream (0.75% or 1.5%) achieved Investigator’s Global Assessment Treatment Success (IGA-TS) than patients treated with a control ... Success was defined as an IGA score of 0 (clear skin
-
Sanofi indicted in France over epilepsy drug birth defects
The following year, France’s social affairs inspection agency IGAS took issue with what it said was a slow response by the health authorities and Sanofi to updating the labelling of ... IGAS has estimated that between 2006 and 2014, somewhere between
-
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial
investigator global assessment (IGA) response of clear or almost clear.
-
J&J's Tremfya filed for approval in US for psoriatic arthritis
CRP), improvement in physical function (HAQ-DI), skin clearance (IGA) and quality of life (SF-36 PCS and MCS).
Novartis receives FDA breakthrough therapy designation for rare disease med
Incyte’s JAK inhibitor cream clears second eczema trial
Sanofi indicted in France over epilepsy drug birth defects
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial
J&J's Tremfya filed for approval in US for psoriatic arthritis
More from news
Approximately 1 fully matching, plus 16 partially matching documents found.
Latest appointments
-
New hires at Nanoform, Leo Pharma and Calliditas
IgA nephropathy (IgAN) – also known as Berger’s disease. ... Currently, there are no approved treatments for IgA Nephropathy, and Nefecon has the potential to be a disease-modifying treatment for patients suffering from this chronic autoimmune disease
New hires at Nanoform, Leo Pharma and Calliditas
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Hayward Medical Communications launch a new, eye-opening journal
Hayward is particularly pleased that the journal features regular columns from the International Glaucoma Association (IGA) and the Royal National Institute of Blind People (RNIB). .
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital account director
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Events Executive
-
Depending on Experience
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital project manager
-
Competitive
-
Digital strategist
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- GSK reveals plans for £400m R&D facility expansion in England
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- AZ’s PNH therapy Ultomiris wins EU backing to expand use for children
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Straight outta lockdown – what’s next for flexible working?
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Onyx Health Launch Creative Studio After Record Year
- Straight outta lockdown – what’s next for flexible working?
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- British officials reportedly monitoring Philip Morris’ proposed acquisition of Vectura
- Kriya Therapeutics raises $100m to further develop gene therapies with ‘broader applications’
- Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial
PMHub
Mind+Matter
We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
